Ipca Laboratories

Ipca Labs slips 5%, hits 52-week low on weak December quarter results

In Q3, Ipca's operating profit margin was lowest since FY19, impacted by lower gross margins, and continued higher overheads.

Ipca Labs Q4 net profit declines 19% at Rs 130 crore on higher expenses

The company had posted a consolidated net profit after tax of Rs 161.34 crore in the same quarter previous fiscal, Ipca Laboratories said in a regulatory filing

Ipca Laboratories' PAT declines 26% to Rs 199.9 crore in December quarter

The company had posted a consolidated net profit of Rs 265.47 crore in the corresponding period last fiscal, Ipca Laboratories said in a regulatory filing

Ipca Labs' board approves acquisition of over 26% stake in Lyka Labs

Lyka Labs is engaged in the manufacturing and marketing of injectables, lyophilized injectables and topical formulations

Lyka Labs hits 5% upper circuit after Ipca buys 1 mn shares via bulk deals

On Monday, Ipca Laboratories purchased 1.05 million equity shares representing 3.65 per cent stake in Lyka Labs at price of Rs 123 per share on the BSE via bulk deals

Ipca Labs second quarter net profit declines 6% to Rs 250 crore

The board declared an interim dividend of Rs 8 per share

3 stock ideas by Osho Krishan of Anand Rathi: Buy Havells, Ipca Labs

Motherson Sumi's stock has seen some buying interest in the past trading sessions and settled well above all its major moving averages on the daily time frame

Drug firm Ipca Laboratories fourth quarter profit up 94% at Rs 161 crore

Shares of Ipca Laboratories were trading at Rs 2,132.30 per scrip on BSE, down 3.06 per cent from the previous close.

Bull run continues; Sensex up 316 pts to end at 43,594, Nifty nears 12,750

All that happened in the markets today.

Pharma shares underperform in a firm market; Glenmark, Ipca Labs fall 6%

In the past month, the S&P BSE Healthcare index underperformed the market by falling 5 per cent, as compared to 5.4 per cent rise in the S&P BSE Sensex

In process of obtaining environmental clearance for new plant in MP: Ipca

Drug maker Ipca Laboratories is in the process of obtaining environmental clearance for a new manufacturing plant in Dewas, Madhya Pradesh, according to its 2019-20 annual report.

Ipca Labs Q1 profit jumps more than 3-folds to Rs 445.68 cr on robust sales

The company had posted a net profit of Rs 129.43 crore for the corresponding period of the previous fiscal, Ipca Labs said in a BSE filing

Ipca Lab hits 52-week high in a range-bound market; stk surges 9% in 3 days

According to Analysts at Phillip Capital, the company's revenues could grow 18 per cent year-on-year (YoY) to Rs 1,272.5 crore in June quarter of FY21

11,300 key level for Nifty ahead of F&O expiry: CapitalVia Global Research

The level of 11,000 might act as support

Domestic growth remains a highlight in IPCA Laboratories' Q4 show

14-17% top line growth estimate indicates 20% rise in earnings

Antiviral drugs see demand surge in India, but segment declines 5.5%

Data from market research firm AIOCD-AWACS shows that sales of oseltamivir (common brand Tamiflu), used against the influenza virus and also for swine flu, went up by 35.8 per cent in April

Ipca and Cadila Healthcare gear up to make drug for coronavirus

Ipca is the biggest producer of the drug. Cadila Healthcare, based in Ahmedabad, too is a major player

Ipca Labs' outlook remains intact with India business on strong footing

Outlook remains intact with India business on strong footing, exports supported by ingredient capabilities

Uptick in domestic segment, biz growth continue to drive Ipca Laboratories

Further rerating of stock will hinge on USFDA resolution

Strong domestic and export growth to drive Ipca Laboratories' earnings

Ipca's first half performance holds testimony to its robust growth with India business growing in mid-teens